Davidson Kempner Capital Management LP purchased a new position in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 268,001 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,727,000. Davidson Kempner Capital Management LP owned about 0.96% of Paratek Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Highbridge Capital Management LLC acquired a new position in Paratek Pharmaceuticals in the 3rd quarter valued at about $5,285,000. Perceptive Advisors LLC acquired a new position in Paratek Pharmaceuticals in the 3rd quarter valued at about $532,000. Alyeska Investment Group L.P. raised its stake in Paratek Pharmaceuticals by 473.4% in the 3rd quarter. Alyeska Investment Group L.P. now owns 916,349 shares of the specialty pharmaceutical company’s stock valued at $23,000,000 after purchasing an additional 756,535 shares during the last quarter. Royce & Associates LP raised its stake in Paratek Pharmaceuticals by 3.6% in the 3rd quarter. Royce & Associates LP now owns 293,200 shares of the specialty pharmaceutical company’s stock valued at $7,359,000 after purchasing an additional 10,300 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in Paratek Pharmaceuticals by 6.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 65,366 shares of the specialty pharmaceutical company’s stock valued at $1,641,000 after purchasing an additional 3,719 shares during the last quarter. 84.30% of the stock is owned by institutional investors and hedge funds.

Shares of Paratek Pharmaceuticals Inc (NASDAQ PRTK) opened at $17.65 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53. Paratek Pharmaceuticals Inc has a fifty-two week low of $13.15 and a fifty-two week high of $29.00.

A number of research analysts have recently commented on PRTK shares. Guggenheim started coverage on shares of Paratek Pharmaceuticals in a research note on Tuesday, October 24th. They set a “buy” rating and a $44.00 price objective for the company. Cantor Fitzgerald set a $50.00 price objective on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 17th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $40.00.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/12/12/davidson-kempner-capital-management-lp-purchases-shares-of-268001-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.